A multicenter, randomized, phase III registration trial of transplantation of NiCord®, ex vivo expanded, UCB-derived, stem and progenitor cells, vs. unmanipulated UCB for patients with hematological malignancies
Completed
This study is an open-label, controlled, multicenter, international, Phase III, randomized study of transplantation of NiCord® versus transplantation of one or two unmanipulated, unrelated cord blood units in patients with acute lymphoblastic leukemia or acute myeloid leukemia, m…
Phase: PHASE3 • Sponsor: Gamida Cell ltd
Last updated Mar 02, 2026 15:25 UTC